Treatment Study
Cytoxan
41 patients indicated they took Cytoxan treatment as their first series or second series if their first series was Watchful Waiting (5). For this entire group the average response time was 2.48 years and the median response time was 2.08 years. The average age of this group was 57.98 years and the median age was 59.8 years. There dose not seem to be any correlation between age and response time. The age span was from 32 to 77.
19 out of the 41 have indicated they have taken a second series of treatment. The average response time for this group was 2.55 years and the median response time was 2.08 years.
22 patients indicated no other treatment at the time they sent in their profile. The average response time for this group was 2.41 years and the median response time was 2.075 years. If and when profiles are updated with more recent information these numbers need to be recalculated.
29 patients indicated they took a combination treatment with Cytoxan. . The average response time for this group was 1.95 years and the median response time was 1.55 years. Only 10 out of the 29 indicated taking a second series of treatment.
Please note the data supplied by patients were ranges not absolute numbers. For this study the average of the range given were used in calculating the following information. These numbers should only be used to show trends.
The average reduction in IgM 6 months after completing the first series of Cytoxan was 2140 and the median was 1500 (Out of the 41 patient profiles only 18 had enough data to calculate a 6 month reduction in IgM).
The average reduction in WBC 6 months after completing the first series of Cytoxan was 0.85 and median was 0.5
The average increase in RBC 6 months after completing the first series of Cytoxan was 0.14 and median was 0.0
The average increase in HGB 6 months after completing the first series of Cytoxan was 1.96 and median was 2.0
Definitions of terms:
Average: Add all the values
in a set numbers and then divide that sum by total of numbers in the set.
Median: The value in the
center of a set of values.
Response
time: Is from the
start of a series of treatment to the start of the next series of treatment.
Series: A set number of courses of a drug. This is followed by an undetermined time period not requiring treatment. For example: 3 Courses of 2CdA over a 6 month period (this is one series) or some quantity of Cytoxan daily/weekly over two years (this is also one series).
|
|
IgM before 1st |
IgM after 1st |
Series1 .6 Month reduction |
IgM before 2nd |
IgM Most Recent |
|
Average |
4832.86 |
2725.69 |
2140.66 |
5099.50 |
1953.20 |
|
Median |
4749.5 |
1749.5 |
1500 |
4999.5 |
1249.5 |
|
|
WBC before 1st |
WBC after 1st |
Series1 6 Month reduction |
WBC before 2nd |
WBC Most Recent |
|
Average |
5.37 |
4.64 |
0.85 |
4.75 |
4.56 |
|
Median |
5.7 |
4.45 |
0.5 |
4.45 |
4.2 |
|
|
RBC before 1st |
RBC after 1st |
Series1 6 Month reduction |
RBC before 2nd |
RBC Most Recent |
|
Average |
3.61 |
3.83 |
-0.14 |
3.58 |
4.03 |
|
Median |
3.7 |
3.7 |
0 |
3.45 |
3.7 |
|
|
HBC before 1st |
HGB after 1st |
Series1 6 Month reduction |
HGB Before 2nd |
HGB Most Recent |
|
Average |
10.23 |
12.19 |
-1.96 |
10.40 |
11.93 |
|
Median |
10.45 |
12.7 |
-2 |
10.45 |
11.7 |
Treatment Side Effects
|
Treatment Text |
|
SideEffects Code |
SideEffect Text |
|
|
Cytoxan (an alkylating agent) |
|
1 |
Fatigue |
28% |
|
|
|
2 |
Weakness |
23% |
|
|
|
3 |
Anemia |
12% |
|
|
|
31 |
Hair Loss or Change |
12% |
|
|
|
6 |
Loss of Appetite |
10% |
|
|
|
9 |
Insomnia |
10% |
|
|
|
12 |
Weight Loss |
10% |
|
|
|
4 |
Lethargy |
8% |
|
|
|
32 |
Peripheral Neuropathy |
8% |
|
|
|
25 |
Hot, Cold or Swollen Feet |
7% |
|
|
|
21 |
Shingles or other Rash |
5% |
|
|
|
99 |
No Side Effects |
9% |
The following data is a small part of the total detail data used to generate all the summary information for this report. The total quantity of material is available upon request.
_______________ indicates patient was on Watchful Waiting before taking their first series of Cytoxan.
_______________ indicates patient took a second series of treatment
_______________ indicates patient took a combination treatment with Cytoxan .
|
Id |
Private |
Age series1 |
Series |
Treatment |
Date from |
Date to |
Response Time |
Response time |
Response time
(ongoing) |
|
558 |
No |
52.79 |
1 |
Cytoxan (an alkylating
agent) Vincristine Other (Specify) |
3/1/2000 |
6/1/2000 |
|
0.31 |
0.31 |
|
76 |
No |
62.42 |
1 |
Cytoxan (an alkylating agent) |
3/1/1992 |
6/1/1994 |
|
7.93 |
7.93 |
|
98 |
No |
50.61 |
2 |
Cytoxan (an alkylating
agent) Fludarabine (a nucleoside analogue) Rituxin |
3/1/1999 |
3/1/2000 |
|
0.93 |
0.93 |
|
241 |
Yes |
48.56 |
1 |
Cytoxan (an alkylating
agent) Vincristine Other (Specify) |
2/1/1985 |
5/1/1985 |
0.24 |
0.24 |
|
_______________ indicates patient was on Watchful Waiting before taking their first series of Cytoxan
|
ID |
IgM before 1st |
IgM after 1st |
Series1 .6 Month reduction |
IgM before 2nd |
IgM Most Recent |
WBC before 1st |
WBC after 1st |
Series1 6 Month reduction |
WBC before 2nd |
WBC Most Recent |
RBC before 1st |
RBC after 1st |
Series1 6 Month reduction |
RBC before 2nd |
RBC Most Recent |
HBC before 1st |
HGB after 1st |
Series1 6 Month reduction |
HGB Before 2nd |
HGB Most Recent |
|
582 |
|
|
|
|
3249.5 |
5.7 |
|
|
|
4.2 |
|
|
|
|
4.2 |
9.7 |
|
|
|
12.2 |
|
549 |
4249.5 |
749.5 |
3500 |
|
|
5.7 |
5.7 |
0 |
|
|
4.7 |
5.2 |
-0.5 |
|
|
13.7 |
14 |
-0.30 |
|
|
|
|